BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19837906)

  • 1. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.
    Li J; Sausville EA; Klein PJ; Morgenstern D; Leamon CP; Messmann RA; LoRusso P
    J Clin Pharmacol; 2009 Dec; 49(12):1467-76. PubMed ID: 19837906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
    Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
    J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
    Leamon CP; Reddy JA; Klein PJ; Vlahov IR; Dorton R; Bloomfield A; Nelson M; Westrick E; Parker N; Bruna K; Vetzel M; Gehrke M; Nicoson JS; Messmann RA; LoRusso PM; Sausville EA
    J Pharmacol Exp Ther; 2011 Feb; 336(2):336-43. PubMed ID: 20978169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
    Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
    Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
    Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
    Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EC145: a novel targeted agent for adenocarcinoma of the lung.
    Pribble P; Edelman MJ
    Expert Opin Investig Drugs; 2012 May; 21(5):755-61. PubMed ID: 22462761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates.
    Vlahov IR; Santhapuram HK; You F; Wang Y; Kleindl PJ; Hahn SJ; Vaughn JF; Reno DS; Leamon CP
    J Org Chem; 2010 Jun; 75(11):3685-91. PubMed ID: 20423159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
    Edelman MJ; Harb WA; Pal SE; Boccia RV; Kraut MJ; Bonomi P; Conley BA; Rogers JS; Messmann RA; Garon EB
    J Thorac Oncol; 2012 Oct; 7(10):1618-21. PubMed ID: 22982661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
    Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
    J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
    Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
    Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
    Dosio F; Milla P; Cattel L
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
    Ambrosio AJ; Suzin D; Palmer EL; Penson RT
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of vinca alkaloids.
    Rahmani R; Zhou XJ
    Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
    Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
    Graybill WS; Coleman RL
    Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
    Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
    Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
    van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
    Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lubiprostone on vinca alkaloid-induced constipation in patients with hematological malignancies: a propensity score-matched analysis.
    Kawada K; Ohta T; Fukuda H; Hayashi T; Tanaka K; Imai T; Morita Y; Miyamura M
    Ann Hematol; 2020 Oct; 99(10):2429-2436. PubMed ID: 32839869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
    Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
    Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.